Printed From BioPortfolio.com
[Comment] Atezolizumab for platinum-treated metastatic urothelial carcinoma
20:08 EST 18 Dec 2017 | The Lancet
In The Lancet, Thomas Powles and colleagues1 report results of the IMvigor211 study—a phase 3 randomised controlled trial assessing the safety and efficacy of atezolizumab versus chemotherapy by programmed death-ligand 1 (PD-L1) expression in 931 patients with platinum-treated metastatic urothelial carcinoma. The primary endpoint, overall survival, was tested hierarchically: first in patients with PD-L1 expression on 5% or more of the immune cells (IC2/3), then in patients with PD-L1 expression on 5% and 1% or more of the immune cells (IC1/2/3), and finally in the intention-to-treat population.
Original Article: [Comment] Atezolizumab for platinum-treated metastatic urothelial carcinoma
